Stockscreener 앱 받기
1.19
0.85%
0.01
시간 외 거래:
1.20
0.01
+0.84%
전일 마감가:
$1.18
열려 있는:
$1.17
하루 거래량:
28,747
Relative Volume:
0.31
시가총액:
$49.85M
수익:
$9.16M
순이익/손실:
$-68.17M
주가수익비율:
-0.7301
EPS:
-1.63
순현금흐름:
$-80.16M
1주 성능:
+4.39%
1개월 성능:
-8.46%
6개월 성능:
-31.21%
1년 성능:
-33.52%
1일 변동 폭
$1.16
$1.1997
1주일 범위
$1.10
$1.20
52주 변동 폭
$0.9707
$1.94
아이케나 온콜로지 Stock (IKNA) Company Profile
명칭
Ikena Oncology Inc
전화
857-343-8292
주소
50 NORTHERN AVE., BOSTON
IKNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.19 | 55.01M | 9.16M | -68.17M | -80.16M | -1.63 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
아이케나 온콜로지 Stock (IKNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-05-04 | 재개 | H.C. Wainwright | Buy |
| 2021-12-23 | 개시 | H.C. Wainwright | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-20 | 개시 | Credit Suisse | Outperform |
| 2021-04-20 | 개시 | Jefferies | Buy |
| 2021-04-20 | 개시 | William Blair | Outperform |
모두보기
아이케나 온콜로지 주식(IKNA)의 최신 뉴스
Ikena Oncology Reports Q1 Loss Amid Merger Plans - TipRanks
Ikena Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Ikena Oncology, Inc. SEC 10-Q Report - TradingView
Renaissance Technologies LLC Sells 70,400 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Geode Capital Management LLC Purchases 56,936 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Prudential Financial Inc. Trims Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology stock hits 52-week low at $0.98 amid market challenges - Investing.com Canada
Ikena Oncology stock hits 52-week low at $0.98 amid market challenges By Investing.com - Investing.com South Africa
Ikena Oncology stock hits 52-week low at $1.21 amid market challenges - Investing.com
Ikena Oncology stock hits 52-week low at $1.21 amid market challenges By Investing.com - Investing.com South Africa
Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Business Wire
Ikena Oncology: Investor Caution as Dividend Payments Remain Unlikely - TipRanks
Ikena Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ikena Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Ikena Oncology, Inc. SEC 10-K Report - TradingView
Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Decreases By 11.8% - MarketBeat
Discovering February 2025's Promising Penny Stocks On US Exchanges - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Stock Price Down 0.7%Here's Why - MarketBeat
A History of Outperforming Analyst Forecasts and Beating the Odds: Ikena Oncology Inc (IKNA) - SETE News
Understanding the Risks of Investing in Ikena Oncology Inc (IKNA) - Knox Daily
Ikena Oncology Merger with Inmagene Biopharmaceuticals and Private Placement Financing - Leerink Partners
Jane Street Group LLC Sells 18,570 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Geode Capital Management LLC Acquires 14,319 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
How former leaders of a sold-off biotech company landed their drugs again - The Business Journals
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Scrip
US Penny Stocks To Watch In January 2025 - Simply Wall St
What Direction Does Ikena Oncology Inc (NASDAQ: IKNA) Analysts Think The Company Will Take? - Stocks Register
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade - MSN
Is Amazon a Buy, Sell, or Hold in 2025? - Yahoo! Voices
Ikena Oncology and Inmagene Biopharmaceuticals to Merger - citybiz
Spruce Biosciences Appoints Interim Chief Medical Officer - MSN
Inmagene takes back-door route to Nasdaq listing - The Pharma Letter
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding from a group of investors - Marketscreener.com
Five things you need to know, and a Chrismukkah throwback - The Business Journals
Mitek Systems (NASDAQ:MITK) Rating Increased to Strong-Buy at StockNews.com - Defense World
Helius Medical Technologies, Inc. Announces First PoNS System Sale to VA Healthcare SystemOn December 23, 2024, Helius Medical Technologies, Inc. (NASDAQ:HSDT) disclosed its successful sale of the first Portable Neuromodulation Stimulator (PoNS) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Purchased by Fmr LLC - Defense World
What is HC Wainwright’s Forecast for CVE:NDA Q1 Earnings? - Defense World
Ikena Oncology Enters into Merger Agreement with Inmagene BiopharmaceuticalsOn December 23, 2024, Ikena Oncology, Inc. (NASDAQ: IKNA) announced a significant development as it entered into a Merger Agreement with Inmagene Biopharmaceuticals. - Defense World
**FibroBiologics Enters Standby Equity Purchase Agreement for $25 Million Financing** ** - Defense World
Moving iMage Technologies Reports Results of Annual Meeting On December 19, 2024, Moving iMage Technologies, Inc. (NYSEAMERICAN: MITQ) held its annual meeting of stockholders. The company disclosed details regarding the meeting through an 8-K - Defense World
D-Wave Quantum Inc. (NYSE:QBTS) Receives $5.63 Consensus Price Target from Analysts - Defense World
Salesforce (NYSE:CRM) Stock Price Down 0% Following Insider Selling - Defense World
Boston biotech opts for reverse merger with San Diego company - The Business Journals
Ikena Oncology and Inmagene Announce Merger and Fundraising - Yahoo Finance
Ikena Oncology (NASDAQ:IKNA) Receives “Neutral” Rating from Wedbush - Defense World
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding - Marketscreener.com
Ikena Oncology's (IKNA) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
아이케나 온콜로지 (IKNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):